European Journal of Dermatology
MENURisk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China Volume 30, numéro 6, November-December 2020
Auteurs
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China
a These authors contributed equally to this work.
- DOI : 10.1684/ejd.2020.3926
- Page(s) : 751-3
- Année de parution : 2020
Since both lupus erythematosus (LE) and rheumatoid arthritis (RA) patients need long-term treatment with immunosuppressive medications [1], they may have an increased risk of viral infection, including SARS-CoV-2 [2, 3]. Hydroxychloroquine (HCQ), a conventional drug for LE or RA, could effectively inhibit SARS-CoV-2 in vitro, while its clinical efficacy remains unclear [4]. Although a randomized trial showed that HCQ cannot prevent symptomatic infection after SARS-CoV-2 exposure [5], more studies [...]